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INTRODUCTION
Cytomegalovirus (CMV) is a very common virus, infect-
ing 50% to 80% of normal adults according to seropreva-
lence surveys of normal blood donors. Reactivation of CMV
following hematopoietic stem cell transplantation (HSCT)
occurs in 60% to 80% of patients who are seropositive
before transplantation or who have seropositive donors. End
organ manifestations of this reactivation can include pneu-
monitis, gastroenteritis, hepatitis, marrow suppression,
retinitis, and encephalitis. Pneumonia is the most common
manifestation among HSCT recipients [1].
Enteritis is the second most common end-organ manifes-
tation of CMV disease after HSCT. Prior to the use of ganci-
clovir therapy, the time to diagnosis of enteritis was described
as a median of 55 to 65 days following transplantation [2].
Twelve small case series published describing 99 patients with
enteritis, some of whom received ganciclovir therapy,
reported an onset of diagnosis at a median of 63 days [1,3-13].
At our center, the development of CMV enteritis
appeared to start beyond 2 months following transplantation,
and this formal retrospective study was undertaken. We
hypothesized that if CMV enteritis was being delayed to later
time points, continuing CMV surveillance in HSCT recipi-
ents might be indicated. This hypothesis would be analogous
to recent observations suggesting that CMV pneumonia can
develop later after transplantation [14], perhaps as a conse-
quence of aggressive ganciclovir therapy for low-level blood-
stream reactivation. We analyzed the onset, risk factors, and
response to therapy for all identiﬁed cases of CMV enteritis.
PATIENTS AND METHODS
Patients
Study patients received medical care at the University of
Minnesota, a large HSCT center in the Minneapolis/Saint
Paul metropolitan area. Patients receiving a first HSCT
between January 1, 1989, and June 30, 2000, were eligible for
evaluation. Follow-up extended for a minimum of 180 days
after the last patient underwent transplantation. Patients
were conditioned for transplantation by the use of chemo-
therapy with or without total body irradiation and received
prophylaxis and treatment for graft-versus-host disease
(GVHD) as previously described [15-17].
From January 1989 until September 1995, CMV-
seropositive patients received high-dose acyclovir prophy-
laxis of 10 mg/kg intravenously (IV) every 8 hours from day
–4 until engraftment, followed by 800 mg orally 5 times daily
until day 100. Herpes simplex virus–seropositive recipients
who were CMV-seronegative and had a CMV-seronegative
donor received half-dose acyclovir. After September 1995,
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CMV-seropositive individuals undergoing allogeneic trans-
plantation were enrolled in a randomized prevention proto-
col examining acyclovir versus ganciclovir. All patients
received ganciclovir 5 mg/kg IV every 12 hours from day –7
to day –2, then acyclovir 10 mg/kg every 8 hours from day
–1 through the day of randomization. When the absolute
neutrophil count recovered to ≥750 cells/mm3 for 2 consecu-
tive days, patients were randomized 1:1 to receive (a) ganci-
clovir 5 mg/kg IV each day Monday through Friday to day
100 or (b) acyclovir 800 mg (or 18 mg/kg) orally 5 times daily
to day 100. This protocol was closed in the summer of 2000.
IV immune globulin (IG) was prescribed by specific
study protocol. From January 1989 to April 1993, allogeneic
recipients received IV IG at 500 mg/kg on days –6, 0, 7, 21,
35, 55, 76, and 98. From May 1993 to 1999, IV IG was given
at the same dose on days –6, 0, 7, 21, and 35. Fungal prophy-
laxis was based on ﬂuconazole. From 1989 to 1991, patients
were randomized to ﬂuconazole 400 mg daily versus placebo
until 14 days following engraftment. During 1992, ﬂucona-
zole 400 mg daily was used for all patients until engraftment.
From 1992 to 1994, patients were randomized to receive
400 mg or 200 mg ﬂuconazole daily until engraftment, fol-
lowed by a second randomization to fluconazole 100 mg
daily or clotrimazole troches from engraftment until day 100.
From 1995 to 2000, patients received fluconazole 200 mg
until engraftment, followed by 100 mg until day 100.
Case Definitions
Invasive enteritis with CMV was defined as gastroin-
testinal signs and symptoms compatible with invasive CMV
disease and evidence of CMV in the gut as diagnosed by
biopsy with characteristic histopathology, virology studies,
immunohistochemistry, or in situ hybridization. Patients
were defined as having pneumonitis secondary to CMV if
there were respiratory signs and symptoms compatible with
invasive CMV disease and virologic evidence of CMV in the
lungs and if they were not already included in the enteritis
category. Bloodstream CMV reactivation (viremia) was
diagnosed using shell vial culture from 1989 to 1995 and
using pp65 antigen testing from 1996 to 2000 [18]. Patients
were defined as having viremia if they were not already
included in the enteritis or pneumonitis categories. Control
patients were those who did not meet any of the case deﬁni-
tions for infection.
Statistical Analysis
The day of onset of CMV enteritis was deﬁned as the
date of the diagnostic specimen. The cumulative incidence of
CMV enteritis was calculated by treating deaths from other
causes as competing risks [19]. We estimated the 2-year post-
transplantation survival by the Kaplan-Meier method [20].
A case-control comparison was made between the cases
of enteritis and the control groups of pneumonitis, viremia,
and no CMV infections. Patient and transplant characteris-
tics were compared across these groups by Pearson’s chi-
square test [21]. Characteristics included age, sex, diagnosis,
conditioning regimen, type of transplant, CMV serostatus,
GVHD prophylaxis, and contributing causes of death. P val-
ues are not reported for cause-of-death subcategories
because they are overlapping.
RESULTS
CMV Enteritis Cases
This series identiﬁed 46 case-patients with CMV enteri-
tis among patients receiving transplants at the University of
Minnesota from January 1, 1989, to June 30, 2000. Diagno-
sis methods included histopathology for 26 of 45 (58%)
cases with pathology reports available and virology for 27 of
44 (61%) cases with virology reports available (Table 1).
Table 1. Efﬁcacy of Diagnostic Methods Performed in First 2 Weeks of
CMV Enteritis Onset*
Unique
Patient Number Esophagus/Stomach/Intestine Colon/Rectum
1061 
1093  
1218  
1253 
1280 
1292  
1347 
1436 
1491 
1533  
1539 
1577 
1583 
1603 
1613 
1640  
1645 
1662  
1692 
1758 
1791 Performed at 
other site
1832 
1852 
1921 
1978 
2143 
2212 
2344 
2377 
2401 
2476  
2480 
2489 
2525 
2555 
2556 
2697 
2780 
3040 
3066 
3138 
3166  
3196  
3201 
3209  
3233  
* indicates pathology studies positive; , pathology studies nega-
tive; , virology positive; , virology negative.
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Eighteen percent of enteritis patients had concordant pathol-
ogy and virology culture results. The median age at the time
of transplantation was 38.9 years (range, 1.5-56.8 years).
The median day of diagnosis of CMV enteritis after marrow
transplantation was day 91 (range, day 17 to day 527) (see
Figure). Survival at 2 years following infection was 35%
(95% confidence interval for 2 years, 21% to 49%). The
median follow-up period for patients surviving the infection
was 3.4 years (range, 7 months to 8 years). Survival for con-
trol patients at 2 years from transplantation is 48% (95%
conﬁdence interval, 46% to 50%) (P < .01).
Patient Demographics
Table 2 displays the comparative demographic informa-
tion for the CMV infection patient groups (enteritis, pneu-
monitis, and bloodstream) and for control patients. The
patients with CMV enteritis infection were significantly
older (age >18 years in 89%). As anticipated, patients with
CMV infection (enteritis, pneumonitis, or bloodstream) were
more likely to have a positive recipient CMV serostatus.
Recipients of autologous grafts and HLA-matched related
were less likely to develop enteritis, whereas unrelated allo-
graft recipients developed CMV infection frequently.
Incidence
Of the 2240 patients receiving transplantations, 46 cases
of CMV enteritis infection were diagnosed, for a cumulative
incidence of 2% (95% conﬁdence interval, 1% to 3% at 2 years
following transplantation). The incidence and time to onset
did not change appreciably from year to year.
Virology and Sites of Recovery
CMV was recovered from upper gastrointestinal sites
(n = 35), lower gastrointestinal sites (n = 7), or both upper
and lower gastrointestinal sites (n = 4) (Table 1). For the
29 (63%) CMV enteritis patients who had viremia preced-
ing enteritis, CMV viremia occurred at a median of 25 days
prior to enteritis (range, 0 to 502 days). For the 10 (22%)
CMV enteritis patients who had viruria preceding enteritis,
CMV viruria occurred at a median of 31 days prior to
enteritis (range, 0 to 393 days).
The vast majority of patients were treated with an 8-week
treatment course of ganciclovir, consisting of 2 weeks of
induction therapy and every-other-day IV IG, followed by
6 weeks of maintenance therapy and twice-weekly IV IG.
Two patients were treated with 3 to 4 weeks of induction
ganciclovir, whereas 1 patient was treated with only 1 week
of induction. In 1993, the maintenance ganciclovir schedule
was changed from 3 times weekly to weekdays. Most
patients received scheduled IV IG with the transplantation
procedure per protocol. One patient was treated with fos-
carnet for CMV enteritis because he had already received
ganciclovir treatment courses for antigenemia. Two patients
received no antiviral treatment because CMV enteritis was
discovered after death.
Seven patients had recurrence of CMV end-organ dis-
ease after initial therapy with 8 weeks of ganciclovir. Gastro-
intestinal CMV recurred at 210, 254, and 609 days, and
pneumonitis occurred at 69, 161, 313, and 417 days follow-
ing the original diagnosis of enteritis.
Death Summary
Thirty-one patients (67%) died at a median of 70 days
(range, 0.1 to 7.1 years) following the diagnosis of CMV
enteritis. The 13 patients who died before the 8-week ganci-
clovir treatment course was completed survived only a
median of 11 days after the diagnosis of CMV enteritis. The
18 patients who survived the treatment course of ganciclovir
died a median of 278 days later.
Clinical determination plus autopsy (n = 19) data for the
31 patients revealed 10 deaths with active CMV infection:
7 involved multiple internal organs, and 3 were restricted to
Time to diagnosis of CMV enteritis from the day of HSCT for 46 patients.
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the lungs. Three cases of gastrointestinal CMV were first
diagnosed at the autopsy: 1 in the jejunum and 2 in the
colon (1 patient was receiving ganciclovir for antigenemia).
Infectious copathogens contributing to CMV-related deaths
included Staphylococcus aureus, Pseudomonas aeruginosa,
parainfluenza-3 virus, Aspergillus fumigatus, and Aspergillus
terreus.
Thirteen patients who died without active CMV disease
had infections other than CMV present at death. Bacterial
pathogens present at death or in the days prior to death
were both gram positive (2 Enterococcus bacteremias, Staphy-
lococcus epidermidis bacteremia, and Micrococcus cultured from
cerebrospinal ﬂuid) and gram negative (2 Enterobacter cloacae,
Citrobacter freundii, and Klebsiella pneumoniae). Fungal organ-
isms included both yeasts (4 Candida fungemias, 1 Saccha-
romyces cerevisiae fungemia, and 1 Candida esophagitis) and
molds (3 Aspergillus infections). One patient had interstitial
pneumonitis attributable to herpes simplex virus.
Table 2. Case Control Analysis of CMV Enteritis Patients*
Viremia, No CMV
Pneumonitis, No Enteritis Infection
Characteristic Enteritis No Enteritis P No Pneumonitis P Control P
n 46 125 247 1822
Age ≥ 18 years (%) 40 (87) 72 (58) <.01 156 (63) <.01 1122 (62) <.01
Male sex (%) 25 (54) 76 (61) NS 119 (48) NS 1004 (55) NS
Oncologic diagnosis (%) <.01 <.01 <.01
CML, chronic phase 23 (50) 26 (21) 55 (22) 309 (17)
Acute leukemia 9 (20) 46 (37) 71 (29) 565 (31)
Myelodysplastic syndrome 6 (13) 9 (7) 14 (6) 69 (4)
Nonmalignant disease 5 (11) 28 (22) 52 (21) 266 (15)
Multiple myeloma 2 (4) 2 (2) 7 (2) 50 (3)
Other 1 (2) 14 (11) 48 (19) 563 (31)
Conditioning regimen (%) .07 NS <.01
Cy/TBI 42 (91) 98 (78) 209 (84) 1239 (68)
Cy/busulfan/other ± ATG 3 (7) 26 (21) 34 (14) 546 (30)
TBI + other drugs 1 (2) 1 (1) 4 (2) 37 (2)
Type of transplant (%) <.01 <.01 <.01
Autologous 2 (4) 16 (13) 44 (18) 798 (44)
Related/HLA-matched 20 (43) 56 (45) 94 (38) 468 (26)
Related/HLA-mismatched 4 (9) 2 (2) 4 (2) 48 (3)
Unrelated 20 (43) 51 (41) 105 (43) 508 (28)
CMV serostatus NS NS <.01
Recipient positive 42 (91) 115 (92) 191 (77) 760 (42)
Recipient negative/donor positive 2 (4) 3 (2) 22 (9) 167 (9)
Recipient negative/donor negative 3 (4) 5 (4) 31 (13) 852 (47)
Missing 0 2 (2) 3 (1) 43 (2)
GVHD prophylaxis (allogeneic only) NS NS NS
(Csp or Tacro) ± MTX ± Pred 34 (77) 87 (80) 144 (71) 803 (78)
T-cell depleted marrow 9 (21) 18 (17) 58 (29) 196 (19)
Other 1 (2) 4 (3) 1 (<1) 25 (3)
GVHD (allogeneic only), % (95% CI)
Grade II-IV acute GVHD prior 70 (57-83) 54 (45-63) 38 (31-44) 39 (36-42) 
to CMV
Grade II-IV acute GVHD after 14 (0-31) 16 (6-26) 19 (13-25) 
CMV (excluding patients with 
prior GVHD)
Chronic GVHD prior to CMV 20 (8-32) 20 (13-27) 7 (0-18) 25 (22-28)
Chronic GVHD after CMV (excluding 58 (38-78) 29 (19-39) 33 (26-40)
patients with prior GVHD)
2-Year survival rate, % (95% CI) 35 (21-49) 32 (24-40) 52 (46-58) 48 (46-50)
Deaths 31 92 129 1039
Contributing causes of death (%)
Relapse 5 (16) 20 (22) 61 (47) 514 (50)
Secondary malignancy 1 (3) 2 (2) 3 (2) 30 (3)
GVHD 21 (68) 54 (59) 70 (54) 732 (70)
CMV, respiratory 6 (19) 41 (45) 0 0
CMV, non-respiratory 7 (23) 7 (8) 8 (6) 0
Other infection (non-CMV) 13 (42) 17 (18) 54 (42) 481 (46)
Other complications 17 (55) 57 (62) 69 (53) 552 (53)
*P values represent chi-square statistical comparisons of the distribution of factors between each cohort with the CMV enteritis group. NS indi-
cates not signiﬁcant (P > .10); CML, chronic myelogenous leukemia; Cy, cyclophosphamide; ATG, antithymocyte globulin; Csp, cyclosporine;
Tacro, tacrolimus; MTX, methotrexate; Pred, prednisone.
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DISCUSSION
This study describes a large cohort of HSCT patients
diagnosed with CMV enteritis since ganciclovir came into
clinical practice. Several observations have emerged from
this study. First, the incidence of CMV enteritis among
HSCT recipients remains low, at 2%. The incidence of
CMV enteritis appears similar over the 11.5 years of
study. Second, our cohort of 46 patients, who underwent
transplantation while ganciclovir was widely used for
treatment of viremia and pneumonitis, demonstrated a
median time to onset of enteritis at day 91, nearly 1 month
later than the median day 60 reported in earlier decades.
Over the decade of study, there was no change in the day
of onset. These findings demonstrate a change in the nat-
ural history of CMV, at least for end-organ disease of the
gastrointestinal tract. The median onset of CMV enteritis
previously reported for 99 patients among 12 nonoverlap-
ping studies was approximately day 63 following trans-
plantation (Table 3). The majority of patients reported in
these studies did not receive ganciclovir as a specific CMV
prophylaxis or preemptive antiviral agent, although
patients in the 2 largest studies did receive ganciclovir
once enteritis developed [6,8].
We observed a steady approximately 2% incidence of
enteritis during the study period. At our center, the underly-
ing etiology of gastrointestinal symptomatology or diarrhea
is aggressively pursued using gastrointestinal biopsy, even of
normal-appearing mucosa. This approach makes underdiag-
nosis of CMV unlikely. In other centers, where endoscopy is
deferred or biopsies of normal-appearing mucosa are not
performed, underdiagnosis of enteritis or presentation of
CMV as viremia or pneumonitis would be expected.
When comparing histopathology with virology data for
the patients in this study cohort, there was only approxi-
mately 20% concordance between the methods. Therefore,
both diagnostic procedures need to be performed in parallel
to ﬁnd all cases of disease. In addition, treatment needs to
be initiated on the basis of either type of study, because a
delay in treatment may increase the morbidity and mortality
associated with CMV enteritis.
The case-control comparison showed that enteritis
occurred more often among older individuals. Autologous
transplantation was less often complicated by enteritis and
by CMV pneumonitis and viremia, as well. The overall inci-
dence of CMV disease is reported to be lower in recipients
of autologous transplantation [22,23].
Most allogeneic transplantation patients at this center
were given IV IG doses as part of the transplantation proce-
dure. During the treatment of CMV enteritis, 500 mg/kg IV
IG was aggressively dosed on an every other day schedule
with ganciclovir induction therapy. IV IG was decreased to
twice weekly for the duration of maintenance therapy. How-
ever, IV IG has not been proven to be an effective adjunct for
CMV enteritis. In a retrospective study of patients with CMV
gastrointestinal disease, 18 of 33 (55%) patients responded to
therapy, including 13 of those treated with antiviral chemo-
therapy alone and 5 of those treated with the combination of
antiviral chemotherapy and IV IG (P value was not signiﬁ-
cant). In a Cox proportional hazards model corrected for
acute GVHD, there was no difference in outcome of CMV
gastrointestinal disease with or without addition of IG [6].
These data suggest that antiviral therapy given as CMV
prophylaxis or other, as yet undeﬁned, clinical factors have
modiﬁed the clinical course and onset of CMV disease. This
Table 3. Literature Case Series of CMV Enteritis in HSCT Recipients
No. of Median Time to Onset,
Study Report Study Dates Patients Studied Day After HSCT (Range) Antiviral Notes
Present report 1/1989 to 6/2000 47 91 (17-527) ACV prophylaxis, then GCV for viremia
[12] 1974 to 1984 1 98 No therapy
[1] 11/1976 to 12/1987 5 40 (17-106) Acyclovir available after 1980
[4] 1/1980 to 7/1994 3, autologous 49 (38-55) Case patients on high-dose ACV 
prophylaxis 1/1987 to 9/1993; control 
groups 1/1980 to 1/1987 and 9/1993 
to 7/1994
[9] 1/1983 to 12/1996 4, all with concurrent 27, 69, 76, 124 Cannot separate from retinitis treatment
CMV retinitis
[11] 7/1986 to 9/1987 3 53, 54, 111 Treatment with GCV
[8] 8/1986 to 8/1988 19, placebo treatment 76 (38-162) Prophylaxis not reported
18, GCV treatment 63 (32-100) Prophylaxis not reported
[7] 7/1989 to 4/1993 1, CMV-seronegative 56 Filtered leukocyte-reduced blood products
[5] 11/1990 to 8/1991 6, placebo prophylaxis 60 (45-74) High-dose ACV, conditioning to engraftment
1, GCV prophylaxis 143 High dose ACV, conditioning to engraftment,
then GCV prophylaxis
[3] 12/1990 to 9/1991 3, allogeneic 55 (46-69) Prophylaxis not reported
[13] Published 1994 1 Approximately 220 Treatment with GCV for 2 weeks
[6] Published 1998 22, antiviral treatment 69 (34-369) Prophylaxis not reported; antiviral 
(no IV IG) treatment: 18 GCV, 4 foscarnet 
11, IV IG in addition 62 (18-194) Prophylaxis not reported; antiviral
to antiviral treatment: 10 GCV, 1 foscarnet
[10] Published 2001 1 44 Treatment with GCV for 6 weeks
*ACV indicates acyclovir; GCV, ganciclovir.
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later onset of serious CMV infection indicates a need for
prolonged CMV surveillance, continued prophylaxis, or
other measures to limit the risks of late CMV infection.
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